Properties (54)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
medication
|
| gptkbp:availableFormats |
implant
depot injection |
| gptkbp:brand |
gptkb:Zoladex
|
| gptkbp:chemicalFormula |
C64H86N18O13S
|
| gptkbp:clinicalTrials |
Phase III
|
| gptkbp:contraindication |
cardiovascular issues
gastrointestinal disturbances pregnancy breastfeeding injection site reactions osteoporosis |
| gptkbp:dosageForm |
10.8 mg implant
10.8 mg injection 3.6 mg implant 7.5 mg injection |
| gptkbp:drugInterdiction |
hormonal therapy
|
| gptkbp:endOfLife |
2-4 hours
|
| gptkbp:healthcare |
bone density
symptom relief hormone levels |
| https://www.w3.org/2000/01/rdf-schema#label |
goserelin
|
| gptkbp:impact |
depends on condition
usually several months to years |
| gptkbp:interactsWith |
anticoagulants
other hormonal therapies |
| gptkbp:isATypeOf |
120287-80-8
|
| gptkbp:lastProduced |
1989
|
| gptkbp:mandates |
hormonal disorders
hormone-sensitive cancers |
| gptkbp:manufacturer |
gptkb:AstraZeneca
|
| gptkbp:marketedAs |
gptkb:Australia
gptkb:Canada gptkb:European_Union gptkb:United_States |
| gptkbp:numberOfStudents |
urine
feces |
| gptkbp:nutritionalValue |
liver
|
| gptkbp:operates_in |
L02AE01
|
| gptkbp:researchAreas |
reproductive health
endocrinology cancer treatment |
| gptkbp:route |
subcutaneous injection
|
| gptkbp:sideEffect |
fatigue
weight gain mood changes hot flashes decreased libido |
| gptkbp:storage |
room temperature
|
| gptkbp:triggerType |
gonadotropin-releasing hormone agonist
|
| gptkbp:usedFor |
breast cancer
prostate cancer endometriosis precocious puberty |